Analysis of the efficacy of giritinib (segatan) in the treatment of acute myeloid leukemia

Gilteritinib (Gilteritinib) is an oral FLT3 inhibitor, mainly used to treat FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML) patients. FLT3gene mutation is one of the common pathogenic factors in AML, which can lead to abnormal proliferation of leukemia cells and disease progression. Giritinib selectively inhibits FLT3 kinase activity and blocks abnormal signaling pathways, thereby inhibiting the growth of leukemia cells and improving the treatment response rate.

Clinical studies have shown that giritinib has significant efficacy in patients with relapsed or refractory AML. In monotherapy trials, the overall response rate of giritinib (including complete response CR and partial response CRh) can reach about 30%-40%, and some patients can obtain durable response. Compared with traditional chemotherapy, giritinib's oral administration and targeted action properties give it advantages in terms of tolerability and quality of life.

Giritinib is also often used in combination with low-dose chemotherapy drugs or other targeted drugs to further improve the response rate and prolong progression-free survival (PFS). Studies have shown that combining azacitidine, nitrogen mustard and other drugs in initial treatment or relapsed AML can enhance the anti-leukemia effect, while reducing the occurrence of serious adverse reactions through dose optimization and treatment course adjustment. Combination treatment strategies provide new treatment options for high-risk patients.

The efficacy of geritinib is affected by many factors, including patient age, FLT3 mutation type (ITD or TKD), combined gene mutations and previous treatment history. It is clinically recommended to conduct comprehensive genotyping and risk assessment before treatment to develop an individualized medication plan. During the treatment process, it is necessary to regularly monitor the changes in blood images and bone marrow morphology, and adjust the dose and course of treatment in a timely manner to optimize the efficacy and reduce side effects, and achieve safe and accurate AML targeted therapy.

Reference materials:https://www.drugs.com/